Research Analysts’ Recent Ratings Changes for Agios Pharmaceuticals (AGIO)

A number of firms have modified their ratings and price targets on shares of Agios Pharmaceuticals (NASDAQ: AGIO) recently:

• 4/21/2026 – Agios Pharmaceuticals had its price target lowered by Bank of America Corporation from $44.00 to $41.00. They now have a “buy” rating on the stock.
• 4/20/2026 – Agios Pharmaceuticals had its price target lowered by HC Wainwright from $65.00 to $50.00. They now have a “buy” rating on the stock.
• 4/6/2026 – Agios Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $31.00 to $36.00. They now have a “neutral” rating on the stock.
• 4/1/2026 – Agios Pharmaceuticals had its price target raised by The Goldman Sachs Group, Inc. from $28.00 to $32.00. They now have a “neutral” rating on the stock.
• 3/27/2026 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 3/22/2026 – Agios Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/14/2026 – Agios Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/5/2026 – Agios Pharmaceuticals had its price target raised by Citigroup Inc. from $38.00 to $46.00. They now have a “buy” rating on the stock.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Krishnan Viswanadhan sold 2,959 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $27.80, for a total value of $82,260.20. Following the completion of the sale, the insider directly owned 5,141 shares of the company’s stock, valued at $142,919.80. This trade represents a 36.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Cecilia Jones sold 3,141 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $109,024.11. Following the completion of the sale, the chief financial officer directly owned 54,998 shares in the company, valued at approximately $1,908,980.58. The trade was a 5.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 15,582 shares of company stock valued at $520,405 over the last 90 days. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.